| Malignant neoplasm of prostate
Posluma vs Eligard
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of prostate.Deep comparison between: Posluma vs Eligard with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEligard has a higher rate of injection site reactions vs Posluma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eligard but not Posluma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Posluma
Eligard
At A Glance
IV injection
PSMA-targeted radiodiagnostic
SC injection
Every 1-6 months
GnRH agonist
Indications
- Malignant neoplasm of prostate
- Malignant neoplasm of prostate
Dosing
Malignant neoplasm of prostate 296 MBq (8 mCi) as a single intravenous bolus injection; begin imaging approximately 60 minutes after administration from mid-thigh to base of skull.
Malignant neoplasm of prostate 7.5 mg SC once every month; 22.5 mg SC once every 3 months; 30 mg SC once every 4 months; 45 mg SC once every 6 months. Injection site should vary periodically in the upper- or mid-abdominal area, upper buttocks, or another location with adequate subcutaneous tissue.
Contraindications
—
- Hypersensitivity to GnRH, GnRH agonist analogs, or any component of ELIGARD
Adverse Reactions
Most common (>=0.4%) Diarrhea, blood pressure increase, injection site pain
Most common (>2%) Hot flashes/sweats, malaise and fatigue, testicular atrophy, weakness, dizziness, nausea, urinary frequency, nocturia, pruritus, myalgia, gynecomastia, decreased libido
Injection site Transient burning/stinging, pain, erythema, bruising, pruritus, induration, ulceration
Postmarketing Pituitary apoplexy, convulsions, interstitial lung disease
Pharmacology
PSMA-targeted radiodiagnostic agent; flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) on prostate cancer cells, which overexpress PSMA, and is internalized; fluorine-18 emits positrons detectable by PET.
Leuprolide acetate is a GnRH agonist that potently inhibits gonadotropin secretion with continuous dosing; chronic administration suppresses LH and FSH, reducing testosterone to below castrate threshold (<=50 ng/dL) in males within two to four weeks of treatment initiation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Posluma.
Eligard
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Posluma.
Eligard
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
No coverage data available for Posluma.
Eligard
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Posluma.
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PoslumaView full Posluma profile
EligardView full Eligard profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.